BMS-833923 - CAS# 1059734-66-5 Size:Solid 10 mg InChi: InChI=1S/C20H20N4O/c25-20(24-13-11-21-12-14-24)16-8-5-15(6-9-16)7-10-19-17-3-1-2-4-18(17)22-23-19/h1-10

InChi: InChI=1S/C20H20N4O/c25-20(24-13-11-21-12-14-24)16-8-5-15(6-9-16)7-10-19-17-3-1-2-4-18(17)22-23-19/h1-10

InChi: InChI=1S/C17H17ClN2O5/c1-3-23-16(21)11(8-19)13-10-7-9(18)5-6-12(10)25-15(20)14(13)17(22)24-4-2/h5-7

96 μM (HEK293 cells) and exhibits 19-fold selectivity against muscarinic receptor-coupled TRPC6 channel activation

is a potent and selective protein degrader

used to treat tuberculosis

BMS-833923 - CAS# 1059734-66-5 Size:Solid 10 mg InChi: InChI=1S/C20H20N4O/c25-20(24-13-11-21-12-14-24)16-8-5-15(6-9-16)7-10-19-17-3-1-2-4-18(17)22-23-19/h1-10BMS 833923, also known as XL 139, is an orally bioavailable small molecule SMO (Smoothened) inhibitor with potential antineoplastic activity. SMO antagonist BMS 833923 inhibits the sonic hedgehog (SHH) pathway protein SMO, which may result in a suppression of the SHH signaling pathway. SMO is a G protein coupled receptor that lies just downstream of the SHH ligand cell surface receptor Patched 1 in the SHH pathway; in the absence of ligand Patched 1